

Appl. No. 09/807,575  
Amdt. dated Jan. 3, 2006  
Reply to Office action of Oct. 11, 2005

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A diagnostic agent for detection of at least one of human breast cancer and pancreatic cancer, comprising: a binding molecule selected from the group consisting of an antibody and an antibody fragment that binds to one of human glypican-1 and to human syndecan-1, and a reporting molecule attached attachable to the binding molecule such that whereby a detection method allows detection of the cancer by detection of ~~can detect~~ the presence of the binding molecule via detection of ~~by detecting~~ the reporting molecule.
2. (Original) The diagnostic agent of Claim 1, wherein the binding molecule comprises an antibody.
3. (Original) The diagnostic agent of Claim 2, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.
4. (Original) The diagnostic agent of Claim 2, wherein the antibody is used to image glypican-1 or syndecan-1.
5. (Currently amended) A composition comprising a therapeutic agent at a concentration effective to slow for slowing growth of at least one of human breast cancer cells and pancreatic human cancer cells, wherein the agent comprises comprising a molecule selected from the group consisting of an antibody and an antibody fragment that affects glypican-1 by one of binding to an extracellular region of human glypican-1, cleaving an extracellular region of [glypican 1] human glypican-1, and suppressing expression of an extracellular region of human glypican-1.
6. (Currently amended) The composition therapeutic agent of Claim 5, wherein the molecule comprises an antibody the binds to the extracellular region of glypican-1.

Appl. No 09/807,575  
Amdt. dated Jan. 3, 2006  
Reply to Office action of Oct. 11, 2005

7. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
8. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.
9. (Withdrawn) A method for diagnosing human cancer comprising the steps of contacting a molecule that binds to one of glypican-1 and syndecan-1 with either a body fluid or body tissue, and detecting the molecule bound to glypican-1 or to syndecan-1.
10. (Withdrawn) The method of Claim 9, wherein the binding molecule comprises an antibody.
11. (Withdrawn) The method of Claim 10, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.
12. (Withdrawn) The method of Claim 10, wherein the antibody is used to image glypican-1 or syndecan-1.
13. (Withdrawn) A method of slowing growth of human cancer cells comprising administering a molecule that affects glypican-1 by one of binding to an extracellular region of glypican-1, cleaving an extracellular region of glypican-1 and suppressing expression of an extracellular region of glypican-1.
14. (Withdrawn) The method of Claim 13, wherein the molecule comprises an antibody the binds to the extracellular region of glypican-1.
15. (Withdrawn) The method of Claim 13, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
16. (Withdrawn) The method of Claim 13, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.